Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder
Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta(R) (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD). This approval — the fourth for duloxetine in Europe — was issued on 28 July following an initial positive opinion issued by the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) on 26 June 2008.
More: continued here
Filed under: Anxiety on September 8th, 2008